Baidu
map

JAMA:脓毒症休克的新定义和临床评价标准

2016-02-23 zhaoshuang 译 MedSci原创

背景和目的:脓毒症休克是指一种与感染有关的急性循环衰竭的状态。新的生物学研究和流行病学挑战改变了其原本定义的有效性。本研究的目的是探讨成人脓毒症休克的新定义和临床标准。

背景和目的:脓毒症休克是指一种与感染有关的急性循环衰竭的状态。新的生物学研究和流行病学挑战改变了其原本定义的有效性。本研究的目的是探讨成人脓毒症休克的新定义和临床标准。

设计,设置和参与者:危重病学会和欧洲重症监护医学会通过召集一个工作组(19名参与者)来修订当前的脓毒症/脓毒症休克的定义。包括3组研究,分别为:(1)对在1992年1月1日和2015年12月25日之间已发表的观察性研究,进行系统回顾和荟萃分析,确定目前报告的临床标准确定的脓毒症休克,并通过“德尔菲”法分析;(2)“德尔菲”法包括根据新的脓毒症休克的定义和临床标准的共识对相关的系统回顾、调查、队列研究的结果的3次调查和讨论;(3)队列研究确定测试变量,数据来自拯救全身性感染行动(Surviving Sepsis Campaign, SSC)(2005-2010年;N = 28   150),匹兹堡大学医学中心(UPMC)(2010-2012年;N = 1 309 025),和加州北部的Kaiser Permanente医学中心(KPNC)(2009-2013年;N = 1 847 165)的电子健康记录(EHR)数据集。

主要成果和措施:对脓毒症休克的定义和标准的协议和措施。

结果:本系统综述从92个脓毒症流行病学研究报告中确定了44个报告过脓毒症休克结果的研究(共166 479例患者)。脓毒症休克–相关的粗死亡率为46.5%(95% CI,42.7% - 50.3%),与统计学的研究间的异质性显著(I2 = 99.5%;τ2 = 182.5;P<  。001)。Delphi法确定低血压、血清乳酸水平和血管加压药治疗作为变量测试队列研究。基于这3个变量单独或组合应用,产生6个病人组。SSC的数据库表明,调整风险后,与其它5组(单单血清乳酸水平大于2 mmol/L,或组合血压过低,血管升压类药物,和血清乳酸水平2 mmol/L或更低)相比,需要升压药才能维持平均血压在65mmHg水平或更高并且血清乳酸水平大于2 mmol/L的患者(18毫克/分升)液体复苏后有较高的死亡率(42.3% [ 95% CI,41.2% - 43.3% ])。这些发现由UPMC和KPNC数据集验证。

结论和意义:基于一个共识的过程中使用的系统回顾、调查和队列研究的结果,脓毒症休克被定义为一类脓毒症,这类患者的基础循环、细胞和代谢异常,且有比单单脓毒症的患者有更高的死亡风险。成人脓毒症休克患者通过临床表现来确定——充分液体复苏后出现低血压,需要血管加压药维持平均血压65mmHg或更高并具有血清乳酸水平大于2 mmol/L。

原始出处:

Manu Shankar-Hari, MD, MSc,et al,Developing a New Definition and Assessing New Clinical Criteria for Septic Shock,For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3),JAMA. 2016;315(8):775-787. doi:10.1001/jama.2016.0289.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]
    2018-03-18 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]
    2018-03-10 1e145228m78(暂无匿称)

    学习了.谢谢作者分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]
    2016-04-10 yydlt

    不错,证据充分

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]
    2016-03-06 1de6ff0am23(暂无匿称)

    不需要sirs和感染指标么

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]
    2016-03-04 1de52159m97(暂无匿称)

    学习了 很不错

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]
    2016-02-25 huagfeg
  10. [GetPortalCommentsPageByObjectIdResponse(id=297385, encodeId=d1eb29e38541, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Mar 18 10:59:43 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294904, encodeId=5617294904f7, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Mar 10 17:40:08 CST 2018, time=2018-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949294, encodeId=4e9619492941c, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Nov 21 16:48:00 CST 2016, time=2016-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661207, encodeId=c929166120eac, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Sat Jun 25 12:48:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966832, encodeId=255219668325b, content=<a href='/topic/show?id=e09323013fd' target=_blank style='color:#2F92EE;'>#临床评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23013, encryptionId=e09323013fd, topicName=临床评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Sun Dec 04 21:48:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77317, encodeId=6f42e73179f, content=不错,证据充分, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Apr 10 20:06:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67626, encodeId=b6276e62699, content=不需要sirs和感染指标么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16301696803, createdName=1de6ff0am23(暂无匿称), createdTime=Sun Mar 06 20:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67224, encodeId=63976e22482, content=学习了 很不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04e41688927, createdName=1de52159m97(暂无匿称), createdTime=Fri Mar 04 22:06:00 CST 2016, time=2016-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444138, encodeId=e1b8144413861, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540289, encodeId=9b6715402893d, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Feb 25 01:48:00 CST 2016, time=2016-02-25, status=1, ipAttribution=)]

相关资讯

Anesthesiology:S1PR2可抑制巨噬细胞并损害宿主对脓毒症的防御能力

脓毒症是指由感染引起的全身炎症反应综合征(SIRS),全身性炎症反应和引发多器官衰竭与死亡的菌血症是脓毒症的两大特征。目前,脓毒症是世界范围内危重病人死亡的主要原因,对脓毒症患者来说,肺通常是最先受累的器官,脓毒症引发的急性呼吸衰竭的死亡率超过40%。尽管生命支持治疗技术不断在进步,但是由于一些菌株对抗菌药物的抗药性不断增加,脓毒症患者生存率的改善依然受到限制。为了解决这些感染性威胁,加强宿主的免

脓毒症:一种陌生却凶险的疾病

文/鲁肃(作者为危重病医学博士) 近日,浙江杭州的一位两岁半幼儿在住院治疗后离世,家长发帖怀疑院方诊治、抢救等方面存在问题。院方则回应建议通过医学鉴定明确责任。暂时抛开这一病例中的纷争,我注意到患儿在入院及后续诊断中都有“败血症(脓毒症)”这一诊断。遗憾的是,这种对小儿、老年及免疫功能下降者十分严重的致命疾病,却很少为人所知。 乍听之下,脓毒症(sepsis)这个疾病的名称真的

专家解读严重脓毒症/脓毒性休克治疗指南

指南简介  脓毒症(sepsis)是由感染引起的全身炎症反应综合征,可发展为严重脓毒症(severe sepsis)和脓毒性休克(septic shock)。随着人口的老龄化、肿瘤发病率上升及侵入性医疗手段的增加,脓毒症的发病率不断上升,每年全球新增数百万脓毒症患者,其中超过1/4患者死亡。按照全球脓毒症联盟公布的数据显示,因脓毒症死亡的人数超过了前列腺癌、乳腺癌、艾滋病死亡人数的总和。过去十

JAMA:脓毒症,医学的一大难题

脓毒症是一种危及生命的疾病,是指由感染引起的全身炎症反应综合征,机体的炎症反应伤及自身组织和器官。每年美国有超过230000名患者出现脓毒症,且他们最初是在在急诊科接受护理。尽管医护人员拼尽全力,仍有1/5的患者最后不幸死亡。在美国医学协会杂志本周的主题,匹兹堡大学的研究人员将在NQF上,将几项有名又重点的临床试验结果汇总为一个简便快捷的临床诊断和处理原则。“NQF汇总了几例特征性的脓毒症患者死亡

Chest:治疗脓毒症期间房颤——β受体阻滞剂优于CCBs

脓毒症期间发生房颤(AF)增加发病率和死亡率,但在脓毒症期间有针对性的治疗AF心率和节律的实践模式和结果目前还不清楚。该项回顾性队列研究的数据来自于约20%的美国医院。研究人员确定了脓毒症期间IV级AF治疗的相关因素(β受体阻滞剂[BBs],钙通道阻滞剂[CCBs],地高辛,或胺碘酮)。研究人员使用倾向得分匹配和工具变量的方法来比较不同治疗房颤方法之间的死亡率。在39693例脓毒症期间发生房颤的患

JAMA:第三次国际共识|脓毒症临床标准评价

第三次国际共识定义任务组将脓毒症定义为“由于机体对感染的特异性反应产生的威胁生命的器官功能障碍”。但对于脓毒症临床表现诊断标准的定义尚不清楚。

Baidu
map
Baidu
map
Baidu
map